Abstract
Combination abacavir/lamivudine/dolutegravir (ABC/3TC/DTG) is approved as a first-line treatment for antiretroviral naïve patients. This report investigated the immunovirological outcome and total HIV-1 DNA decay in a small cohort of naïve HIV-1-positive patients treated with this regimen. In the presence of viral suppression and increased lymphocyte T CD4+ cells, the quantitative analysis of total HIV-1 DNA content revealed a significant decay after 12 months of treatment. Subsequently, we deintensificated the treatment of these patients from (ABC/3TC/DTG) to lamivudine plus dolutegravir (3TC/DTG) after 12 months of virological suppression, as a strategy of "induction-maintenance" therapy. The analysis of HIV-1 RNA viral load, total HIV-1 DNA, CD4+ T lymphocyte count and CD8+ HLA-DR+ T lymphocyte percentage after a mean 3.5 months of therapy deintensification showed no significant difference with respect to data detected after 12 months of ABC/3TC/DTG treatment in the presence of continuous viral suppression. These results indicate that the deintensification of highly active antiretroviral therapy (HAART) from ABC/ 3TC/DTG to 3TC/DTG effectively controls HIV-1 replication and in the early period does not induce any significant variations of total HIV-1 DNA. This suggests that HAART deintensification might be proposed as a therapeutic evolution in the treatment of HIV-1 infection.
| Original language | English |
|---|---|
| Pages (from-to) | 262-267 |
| Number of pages | 6 |
| Journal | The new microbiologica |
| Volume | 41 |
| Issue number | 4 |
| Publication status | Published - Oct 1 2018 |
Fingerprint
Keywords
- Abacavir/lamivudine/dolutegravir
- Deintensification
- HAART
- HIV DNA decay
ASJC Scopus subject areas
- Microbiology (medical)
Cite this
Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir. / Lanzafame, Massimiliano; Nicole, Stefano; Rizzardo, Sebastiano; Piacentini, Daniela; Chiesi, Sheila; Lattuada, Emanuela; Diani, Erica; Carelli, Maria; Vento, Sandro; Gibellini, Davide.
In: The new microbiologica, Vol. 41, No. 4, 01.10.2018, p. 262-267.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir
AU - Lanzafame, Massimiliano
AU - Nicole, Stefano
AU - Rizzardo, Sebastiano
AU - Piacentini, Daniela
AU - Chiesi, Sheila
AU - Lattuada, Emanuela
AU - Diani, Erica
AU - Carelli, Maria
AU - Vento, Sandro
AU - Gibellini, Davide
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Combination abacavir/lamivudine/dolutegravir (ABC/3TC/DTG) is approved as a first-line treatment for antiretroviral naïve patients. This report investigated the immunovirological outcome and total HIV-1 DNA decay in a small cohort of naïve HIV-1-positive patients treated with this regimen. In the presence of viral suppression and increased lymphocyte T CD4+ cells, the quantitative analysis of total HIV-1 DNA content revealed a significant decay after 12 months of treatment. Subsequently, we deintensificated the treatment of these patients from (ABC/3TC/DTG) to lamivudine plus dolutegravir (3TC/DTG) after 12 months of virological suppression, as a strategy of "induction-maintenance" therapy. The analysis of HIV-1 RNA viral load, total HIV-1 DNA, CD4+ T lymphocyte count and CD8+ HLA-DR+ T lymphocyte percentage after a mean 3.5 months of therapy deintensification showed no significant difference with respect to data detected after 12 months of ABC/3TC/DTG treatment in the presence of continuous viral suppression. These results indicate that the deintensification of highly active antiretroviral therapy (HAART) from ABC/ 3TC/DTG to 3TC/DTG effectively controls HIV-1 replication and in the early period does not induce any significant variations of total HIV-1 DNA. This suggests that HAART deintensification might be proposed as a therapeutic evolution in the treatment of HIV-1 infection.
AB - Combination abacavir/lamivudine/dolutegravir (ABC/3TC/DTG) is approved as a first-line treatment for antiretroviral naïve patients. This report investigated the immunovirological outcome and total HIV-1 DNA decay in a small cohort of naïve HIV-1-positive patients treated with this regimen. In the presence of viral suppression and increased lymphocyte T CD4+ cells, the quantitative analysis of total HIV-1 DNA content revealed a significant decay after 12 months of treatment. Subsequently, we deintensificated the treatment of these patients from (ABC/3TC/DTG) to lamivudine plus dolutegravir (3TC/DTG) after 12 months of virological suppression, as a strategy of "induction-maintenance" therapy. The analysis of HIV-1 RNA viral load, total HIV-1 DNA, CD4+ T lymphocyte count and CD8+ HLA-DR+ T lymphocyte percentage after a mean 3.5 months of therapy deintensification showed no significant difference with respect to data detected after 12 months of ABC/3TC/DTG treatment in the presence of continuous viral suppression. These results indicate that the deintensification of highly active antiretroviral therapy (HAART) from ABC/ 3TC/DTG to 3TC/DTG effectively controls HIV-1 replication and in the early period does not induce any significant variations of total HIV-1 DNA. This suggests that HAART deintensification might be proposed as a therapeutic evolution in the treatment of HIV-1 infection.
KW - Abacavir/lamivudine/dolutegravir
KW - Deintensification
KW - HAART
KW - HIV DNA decay
UR - http://www.scopus.com/inward/record.url?scp=85059494120&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059494120&partnerID=8YFLogxK
M3 - Article
C2 - 30311623
AN - SCOPUS:85059494120
VL - 41
SP - 262
EP - 267
JO - New Microbiologica
JF - New Microbiologica
SN - 1121-7138
IS - 4
ER -